Investing.com - agilon health (NYSE: AGL) reported fourth quarter EPS of $-0.41, $0.17 worse than the analyst estimate of $-0.24. Revenue for the quarter came in at $1.06B versus the consensus estimate of $1.02B.
Guidance
agilon health sees Q1 2024 revenue of $1.61B-$1.63B versus the analyst consensus of $1.60B.
agilon health sees FY 2024 revenue of $6.35B-$6.42B versus the analyst consensus of $6.38B.
agilon health's stock price closed at $6.28. It is down -44.33% in the last 3 months and down -69.45% in the last 12 months.
agilon health saw 0 positive EPS revisions and 3 negative EPS revisions in the last 90 days. See agilon health's stock price’s past reactions to earnings here.
According to InvestingPro, agilon health's Financial Health score is "good performance".
Check out agilon health's recent earnings performance, and agilon health's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar